$KPTI
Karyopharm Therapeutics Inc.

2018 Q3 Form 10-Q Financial Statement

#000119312518241301 Filed on August 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $239.0K $19.89M $3.000K
YoY Change 662933.33% -94.92%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.97M $9.490M $6.640M
YoY Change 122.85% 42.92% 11.41%
% of Gross Profit
Research & Development $36.43M $44.73M $23.12M
YoY Change 44.34% 93.49% -5.94%
% of Gross Profit
Depreciation & Amortization $190.0K $180.0K $180.0K
YoY Change 5.56% 0.0% 0.0%
% of Gross Profit
Operating Expenses $49.39M $54.22M $29.76M
YoY Change 59.05% 82.23% -2.55%
Operating Profit -$49.15M -$34.33M -$29.75M
YoY Change 58.28% 15.39% -2.38%
Interest Expense $1.100M $650.0K $410.0K
YoY Change 144.44% 58.54% 24.24%
% of Operating Profit
Other Income/Expense, Net $1.085M $660.0K $383.0K
YoY Change 153.5% 72.32% 20.44%
Pretax Income -$48.07M -$33.67M -$29.37M
YoY Change 56.95% 14.65% -2.62%
Income Tax $14.00K -$17.00K $18.00K
% Of Pretax Income
Net Earnings -$48.08M -$33.66M -$29.39M
YoY Change 56.93% 14.52% -2.56%
Net Earnings / Revenue -20118.41% -169.2% -979566.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$793.5K -$600.1K -$641.3K
COMMON SHARES
Basic Shares Outstanding 60.56M shares 49.85M shares 47.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $206.8M $241.1M $143.5M
YoY Change 73.17% 68.03% 16.95%
Cash & Equivalents $101.6M $119.0M $55.38M
Short-Term Investments $105.2M $122.2M $88.10M
Other Short-Term Assets $4.800M $3.400M $2.300M
YoY Change 108.7% 47.83% 53.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $211.6M $244.6M $145.7M
YoY Change 73.86% 67.82% 17.33%
LONG-TERM ASSETS
Property, Plant & Equipment $2.914M $2.611M $2.473M
YoY Change 26.48% 5.58% -21.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.800M $8.800M $37.30M
YoY Change -87.85% -76.41% -13.05%
Other Assets $700.0K $600.0K $300.0K
YoY Change 133.33% 100.0% 170.27%
Total Long-Term Assets $8.430M $12.03M $40.03M
YoY Change -79.97% -69.94% -14.29%
TOTAL ASSETS
Total Short-Term Assets $211.6M $244.6M $145.7M
Total Long-Term Assets $8.430M $12.03M $40.03M
Total Assets $220.0M $256.6M $185.8M
YoY Change 34.33% 38.14% 8.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.238M $3.794M $3.247M
YoY Change 18.41% 16.85% -20.08%
Accrued Expenses $29.16M $22.97M $12.88M
YoY Change 64.58% 78.39% 15.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.57M $36.54M $17.52M
YoY Change 96.49% 108.58% 12.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.300M $6.600M $1.500M
YoY Change 421.43% 340.0% -16.67%
Total Long-Term Liabilities $7.300M $6.600M $1.500M
YoY Change 421.43% 340.0% -16.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.57M $36.54M $17.52M
Total Long-Term Liabilities $7.300M $6.600M $1.500M
Total Liabilities $48.91M $43.12M $19.04M
YoY Change 116.47% 126.5% 9.84%
SHAREHOLDERS EQUITY
Retained Earnings -$615.5M -$567.5M -$425.7M
YoY Change 34.9% 33.31% 35.67%
Common Stock $786.8M $781.2M $592.5M
YoY Change 31.66% 31.84% 26.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $171.1M $213.5M $166.7M
YoY Change
Total Liabilities & Shareholders Equity $220.0M $256.6M $185.8M
YoY Change 34.33% 38.14% 8.69%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$48.08M -$33.66M -$29.39M
YoY Change 56.93% 14.52% -2.56%
Depreciation, Depletion And Amortization $190.0K $180.0K $180.0K
YoY Change 5.56% 0.0% 0.0%
Cash From Operating Activities -$38.67M -$37.63M -$21.72M
YoY Change 77.79% 73.25% 3.97%
INVESTING ACTIVITIES
Capital Expenditures -$490.0K -$400.0K
YoY Change 4800.0%
Acquisitions
YoY Change
Other Investing Activities $21.06M -$27.21M -$1.140M
YoY Change 2.18% 2286.84% -107.03%
Cash From Investing Activities $20.57M -$27.60M -$1.140M
YoY Change -0.15% 2321.05% -107.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 770.0K 147.1M 52.57M
YoY Change 381.25% 179.87% 21804.17%
NET CHANGE
Cash From Operating Activities -38.67M -37.63M -21.72M
Cash From Investing Activities 20.57M -27.60M -1.140M
Cash From Financing Activities 770.0K 147.1M 52.57M
Net Change In Cash -17.33M 81.90M 29.71M
YoY Change 1650.51% 175.66% -770.65%
FREE CASH FLOW
Cash From Operating Activities -$38.67M -$37.63M -$21.72M
Capital Expenditures -$490.0K -$400.0K
Free Cash Flow -$38.18M -$37.23M
YoY Change 75.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60563449 shares
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55381000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55865000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
284000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22969000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
244559000
CY2018Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
179908000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1894000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2911000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
781180000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3794000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-260000
CY2018Q2 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
48 Securities
CY2018Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
131194000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
122155000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118966000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119604000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q2 us-gaap Assets
Assets
256589000
CY2018Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
262000
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
96837000
CY2018Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2018Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
130936000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
8781000
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60501260 shares
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60501260 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
189000
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2041000
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9363000
CY2018Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4532000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4372000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
36544000
CY2018Q2 us-gaap Liabilities
Liabilities
43117000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256589000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
551000
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
229000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2611000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3438000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
638000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5522000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-567454000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
213472000
CY2018Q2 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16152000
CY2018Q2 kpti Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
249902000
CY2018Q2 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50142000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21445000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
148423000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
148673000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
972000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2558000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
106868000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
625017000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5665000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-217000
CY2017Q4 us-gaap Assets
Assets
180294000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
256000
CY2017Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
96623000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
29396000
CY2017Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
54 Securities
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
107121000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77472000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68997000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69487000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49533150 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49533150 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
303000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1363000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21921000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3982000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49467000
CY2017Q4 us-gaap Liabilities
Liabilities
50830000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180294000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
133000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2185000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1754000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
290000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4743000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495341000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
129464000
CY2017Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
16198000
CY2017Q4 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-592000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5723000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59195000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
363000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.35
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12899000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59263000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1507000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1484000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1025000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
139000
us-gaap Investment Income Interest
InvestmentIncomeInterest
812000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
768000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-585000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52626000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46429000
us-gaap Net Income Loss
NetIncomeLoss
-59304000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
84000
us-gaap Operating Expenses
OperatingExpenses
60102000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60031000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
598000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
61564000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
303000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
60979000
us-gaap Profit Loss
ProfitLoss
-59304000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47203000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71000
us-gaap Share Based Compensation
ShareBasedCompensation
11038000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43873892 shares
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
52323000
dei Amendment Flag
AmendmentFlag
false
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-270000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-44000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50117000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72157000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Depreciation And Amortization
DepreciationAndAmortization
353000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.36
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1624000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1685000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8026000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-564000
dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17110000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72119000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1870000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1162000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1155000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25120000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
147561000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72280000
us-gaap Net Income Loss
NetIncomeLoss
-72114000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-38000
us-gaap Operating Expenses
OperatingExpenses
103165000
us-gaap Operating Income Loss
OperatingIncomeLoss
-73274000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
803000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
74943000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
779000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1841000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
50602000
us-gaap Profit Loss
ProfitLoss
-72114000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86055000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29891000
us-gaap Share Based Compensation
ShareBasedCompensation
8604000
dei Trading Symbol
TradingSymbol
KPTI
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
653000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52862194 shares
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
145720000
CY2017 kpti Tax Cuts And Jobs Act Of2017 Change In Tax Rate Reduction In Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateReductionInDeferredTaxAssets
42763000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29348000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6635000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29369000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
412000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
383000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-29387000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
73000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
29755000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29752000
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
297000
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-34000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23120000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45831239 shares
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33629000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9489000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33672000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-17000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
660000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-33655000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-78000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
54223000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-34332000
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
430000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
104000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44734000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19891000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56089159 shares

Files In Submission

Name View Source Status
0001193125-18-241301-index-headers.html Edgar Link pending
0001193125-18-241301-index.html Edgar Link pending
0001193125-18-241301.txt Edgar Link pending
0001193125-18-241301-xbrl.zip Edgar Link pending
d498055d10q.htm Edgar Link pending
d498055dex101.htm Edgar Link pending
d498055dex102.htm Edgar Link pending
d498055dex103.htm Edgar Link pending
d498055dex104.htm Edgar Link pending
d498055dex311.htm Edgar Link pending
d498055dex312.htm Edgar Link pending
d498055dex321.htm Edgar Link pending
d498055dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4980551.jpg Edgar Link pending
g4980552.jpg Edgar Link pending
g498055dsp022.jpg Edgar Link pending
g498055dsp023.jpg Edgar Link pending
g498055dsp024.jpg Edgar Link pending
g498055dsp025.jpg Edgar Link pending
g498055dsp026.jpg Edgar Link pending
g498055dsp027.jpg Edgar Link pending
g498055dsp028.jpg Edgar Link pending
g498055dsp029.jpg Edgar Link pending
g498055dsp030.jpg Edgar Link pending
g498055dsp031.jpg Edgar Link pending
g498055dsp032.jpg Edgar Link pending
g498055dsp033.jpg Edgar Link pending
g498055dsp034.jpg Edgar Link pending
g498055dsp035.jpg Edgar Link pending
g498055g0725205200395.jpg Edgar Link pending
g498055g0725205206274.jpg Edgar Link pending
g498055g0725205206486.jpg Edgar Link pending
g498055snap0003.jpg Edgar Link pending
kpti-20180630.xml Edgar Link completed
kpti-20180630.xsd Edgar Link pending
kpti-20180630_cal.xml Edgar Link unprocessable
kpti-20180630_def.xml Edgar Link unprocessable
kpti-20180630_lab.xml Edgar Link unprocessable
kpti-20180630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending